Search
Breast conservation therapy as an initial treatment did not compromise survival outcomes compared to mastectomy in breast cancer patients under the age of 35.
Three 2010 summer students won poster awards at the Annual Biomedical Research Conference for Minority Students in November.
Carl Granum tells the story of his diagnosis and treatment for a desmoplastic small round cell tumor, a type of sarcoma that typically begins in the abdomen or pelvis.
— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.
The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.
In a plenary presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, Dr. Dana Pe’er highlighted three recent research collaborations between her lab and other labs at MSK that have shed new light on the ability of cancer cells to adapt and spread.
The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a 468-gene oncopanel intended to detect gene mutations and other critical genetic aberrations in both rare and common cancers.
For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.
Por primera vez, un fármaco dirigido está mostrando resultados prometedores en el tratamiento del cáncer pulmonar de células no pequeñas causado por una mutación llamada KRAS-G12D.